Join moderator Caroline DiCristo, PharmD, Associate Medical Director – Zanidatamab of Jazz Pharmaceuticals, alongside Dr. Noman Ashraf of Tampa General Hospital Cancer Institute and Dr. Umair Majeed of Mayo Clinic in Jacksonville for the third installment of the Advancing Care in GI and Biliary Tract Cancers podcast series. This episode explores HER2-targeted agents in GI malignancies, with a focus on understanding their distinct mechanisms of action and how these differences influence treatment selection.

HER2 alterations are increasingly recognized across biliary tract, gastric, and colorectal cancers, with a growing number of targeted therapies available. As treatment options expand, understanding how each class of HER2-directed therapy works has become essential for optimizing patient outcomes and tailoring care based o ...